Canada OK’s Pot-based Drug
In a boon for medicinal marijuana advocates, Canada has approved the sale of a drug derived from cannabis to treat multiple sclerosis-related nerve pain.
This week’s approval of Sativex marked the world’s first cannabis-based drug to reach the market, according to the drug’s U.K.-based manufacturer, GW Pharmaceuticals. Approved by Canada’s regulatory body, Health Canada, the cannabis-derived spray should hit the market in late spring.
Shares of GW rose by 0.75 percent Wednesday on the London Stock Exchange.